Tri-Tren 150 (Trenbolone Blend)

Tri-Tren 150 (Trenbolone Blend) — Trenbolone Enanthate combines the unmatched anabolic power of Trenbolone with the dosing convenience of a long-acting enanthate es...

€70,00

In Stock (100 available)

British Dragon · Tri-Tren 150 (Trenbolone Blend) — Trenbolone Enanthate combines the unmatched anabolic power of Trenbolone with the dosing convenience of a long-acting enanthate es…

100 in stock

5+ −10%

10+ −15% Best price

Third-Party Lab Report HPLC verified

CoA available on request — email support@vitalquests.org with the batch code from your vial.

HPLC TestedBatch report available

No Labels on BoxPlain brown parcel

Pay the CourierCash on delivery only

Ships TodayOrder before 14:00

€85+ = free shipping

EU warehouse — no customs, no delays

Tracked via DHL / DPD / InPost

Description

This the manufacturer tren E at delivers trenbolone’s full mechanism (5× androgen-receptor affinity, glucocorticoid binding, nutrient partitioning) with a longer release profile than acetate. Pair with testosterone at TRT dose minimum.

Key Benefits

Multi-ester 19-nor trenbolone — acute kick + sustained coverage
Typical mix: acetate + enanthate + hexahydrobenzylcarbonate
Injection frequency every 3–4 days sufficient
Active molecule identical to single-ester tren at AR level
Same side-effect burden as standalone tren — blend isn’t softer

Recommended Dosage

Research dosing: 150–300 mg/week split across 2–3 injections. The acetate fraction peaks within a day while longer esters build steady-state over 3–4 weeks. Cycles 10–12 weeks.

How It Works

Blend of trenbolone acetate, enanthate, and hexahydrobenzylcarbonate (parabolan) — all three are 19-nor derivatives with the same extreme AR affinity as single-ester trenbolone. Progestagenic. The blend provides staggered release: acetate in ~24 h, enanthate ~7 days, hexa ~10 days. At the receptor level the active molecule is identical across esters.

Pharmacokinetics

Composite release profile. Faster kick-in than pure enanthate, flatter serum than pure acetate. Injection frequency every 3–4 days adequate. Steady-state in 3–4 weeks.

Potential Side Effects

Identical to single-ester tren: prolactin rise, night sweats, insomnia, CV stress, aggression. Caber 0.25 mg 2×/week mandatory. Bloodwork including prolactin at week 6.

Cycle & Stacking Guide

Cutting and recomp cycles 10–12 weeks. Test E 300–500 mg/week + tren blend 200–300 mg/week. Attention to sleep, resting HR, and lipids throughout. Not for first or second cycles.

Storage & Handling

Store upright at 15–25 °C in the original box, protected from light and moisture. Oil-based injectables are shelf-stable for the duration printed on the vial when kept at controlled room temperature. Do not refrigerate — cold thickens the carrier oil and makes drawing/injecting harder. Keep out of reach of children. For research and educational purposes only.

Reviews

There are no reviews yet.

Be the first to review “Tri-Tren 150 (Trenbolone Blend)”

2D structural representation · PubChem CID 24822 ↗

Chemical Identity
#	CAS Registry Number	`10161-34-9`
Σ	IUPAC Name	[(8S,13S,14S,17S)-13-methyl-3-oxo-2,3,6,7,8,14-hexahydro-1H-cyclopenta[a]phenanthrene-17-yl] acetate
F	Molecular Formula	C₂₀H₂₄O₃
M	Molecular Weight	312.41 g/mol
⌬	SMILES	`CC(=O)O[C@@H]1CC[C@@H]2C3=CC=C4CC(=O)CC[C@]4(C)[C@@H]3CC[C@]12C`
⊞	InChIKey	`FNYKCQMZFXUVMA-LKBHZCJUSA-N`
△	Melting Point	96-97 °C
≋	Solubility	Practically insoluble in water; soluble in oils and organic solvents
t½	Biological Half-life	1 day (IM)
⊕	PubChem CID	24822 ↗

Pharmacological Profile
Anabolic Rating	500
Androgenic Rating	500
Aromatization	None
Hepatotoxicity	Low
Detection Time	5 months

Clinical Notes

Mechanism & protocol-relevant pharmacology, reviewed by editorial pharmacology lead

19-nor 5alpha-reduced analogue of nandrolone. Non-aromatizable — AR-binding affinity roughly 5x testosterone, with measurable agonist activity at the progesterone receptor. The acetate ester generates fast serum peaks and drops; EOD administration is the floor for stable concentrations. Clinical picture: rapid lean-tissue accretion independent of caloric surplus, reduced adipose mass via direct AR signalling in adipocytes, pronounced lipid shift (HDL suppression 40–60%). Prolactin elevation occurs in a subset — cabergoline 0.25 mg twice weekly is the standard response. Renal biomarkers (creatinine, cystatin C) commonly shift upward; this reflects haem metabolite excretion in urine (brick-red pigment) rather than confirmed nephrotoxicity, but CKD-EPI readings should be interpreted with the confounding documented. Nocturnal sympathetic tone (insomnia, diaphoresis) is dose-dependent and resolves on cessation.

Known trade names: Finajet, Finaplix, Trenbol

External references

Data sourced from published pharmacological literature and authoritative chemical databases (PubChem, DrugBank, ChEBI). Provided for identification and research reference only.

Tri-Tren 150 (Trenbolone Blend)